Roche Diagnostics Corporation v. Meso Scale Diagnostics, LLC, No. 21-1609 (Fed. Cir. Apr. 8, 2022)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Roche Diagnostics Corporation and BioVeris Corpora- tion (collectively, “Roche”) appeal a final judgment from the District of Delaware sustaining the jury’s verdict that Roche violated exclusive license rights belonging to Meso Scale Diagnostics, LLC (“Meso”) by directly infringing one patent claim and inducing infringement of three other pa- tent claims.